|
|
Company News
All Releases
 |
Achillion Announces Executive Promotion
May 18, 2012
|
10.5 KB |
|
| |
NEW HAVEN, Conn., May 18, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the promotion of Gautam Shah, Ph.D. to Executive Vice President. Dr. Shah maintains his position as Chief Compliance O...
|
|
ACH-3102 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
May 15, 2012
|
13.5 KB |
|
| |
NEW HAVEN, Conn., May 15, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACH-3102 as part of an interferon-free regimen for the treatment of chronic hepatitis C (HCV). ACH-3102 is a pan-genotypic second-generation NS5...
|
|
Achillion Reports First Quarter 2012 Financial Results
May 9, 2012
|
17.0 KB |
|
| |
NEW HAVEN, Conn., May 9, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three months ended March 31, 2012. For the first quarter of 2012, the Company reported a net l...
|
|
Achillion Advances Second Generation Pan-Genotypic NS5A Inhibitor, ACH-3102, Into Clinical Development
May 9, 2012
|
12.1 KB |
|
| |
NEW HAVEN, Conn., May 9, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today announced that it has begun dosing ACH-3102 in a Phase 1 clinical trial. ACH-3102 is Achillion's second generation pan-genotypic NS5A inhibitor being investigated for the treatment of chronic hepatitis C virus (HCV) infection.
ACH-3102 is a str...
|
|
Achillion Clarifies End of Treatment Data From Phase 2a Trial With ACH-1625 Based Regimen in Hepatitis C
Apr 23, 2012
|
13.8 KB |
|
| |
NEW HAVEN, Conn., April 23, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN) today provided clarification with respect to end of treatment (EOT) data from segment 2 of its Phase 2a trial of ACH-1625 that was presented during the 47th Annual Meeting of the European Association for the Study of the Liver (EASL) International Liv...
|
|
Achillion Announces 94 - 100% Complete EVR From Phase 2 Trial With ACH-1625 Based Regimen in Hepatitis C
Apr 21, 2012
|
16.1 KB |
|
| |
NEW HAVEN, Conn., April 21, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that in the second segment of its Phase 2a trial of ACH-1625, 94 to 100 percent of patients with treatment naïv...
|
|
Achillion Reports 2011 Fourth Quarter and Year-End Financial Results
Mar 8, 2012
|
21.4 KB |
|
| |
NEW HAVEN, Conn., March 8, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and twelve months ended December 31, 2011.
For the three months ended December 31,...
|
|
Achillion Fourth Quarter and Full Year 2011 Financial Release and Conference Call Alert
Mar 2, 2012
|
9.1 KB |
|
| |
NEW HAVEN, Conn., March 2, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that it plans to release fourth quarter and full year 2011 financial results on Thursday, March 8, 2012, before the m...
|
|
Achillion to Present at Two Upcoming Investor Conferences
Mar 1, 2012
|
8.3 KB |
|
| |
NEW HAVEN, Conn., March 1, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that members of the executive team will provide a corporate update at the following upcoming investor conferences:
...
|
|
Virology Profile Following Treatment With ACH-1625 Discussed in Oral Presentation at 2012 Asian Pacific Liver Conference
Feb 16, 2012
|
11.5 KB |
|
| |
NEW HAVEN, Conn., Feb. 16, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that novel preclinical and clinical virology data on ACH-1625, a Phase 2 pan-genotypic protease inhibitor, was presen...
|
|
Achillion to Present at Three Upcoming Investor Conferences
Feb 8, 2012
|
9.0 KB |
|
| |
NEW HAVEN, Conn., Feb. 8, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Michael Kishbauch, President and Chief Executive Officer of Achillion, will provide a corporate update at the fol...
|
|
Achillion Announces Executive Promotion
Feb 3, 2012
|
9.0 KB |
|
| |
NEW HAVEN, Conn., Feb. 3, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the promotion of Mr. Joseph Truitt to Senior Vice President of Business Development. Mr. Truitt maintains his position...
|
|
Achillion to Present at the Noble Financial Capital Markets' Eighth Annual Equity Conference
Jan 13, 2012
|
8.1 KB |
|
| |
NEW HAVEN, Conn., Jan. 13, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Joseph Truitt, Senior Vice President of Business Development and Chief Commercial Officer of Achillion, will pre...
|
|
Achillion Reports Clinical Data on Portfolio of Protease Inhibitors
Jan 9, 2012
|
20.0 KB |
|
| |
Once-daily ACH-1625 safe, well-tolerated and achieves 100% cEVR after 12 weeks of treatmentPilot study of ACH-1625 in HCV genotype 3 achieves maximal 3.68 log10 reductionACH-2684 safe, well tolerated and achieves HCV genotype 1 maximal 4.63 log10 reduction; Additional dosing on-going
NEW HAVEN, Conn., Jan. 9, 2012 (GLOBE NEWSWIRE) -- Achillion ...
|
|
ACH-1625 Receives Fast Track Designation From the FDA for the Treatment of Chronic Hepatitis C
Jan 4, 2012
|
13.5 KB |
|
| |
NEW HAVEN, Conn., Jan. 4, 2012 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, announced today the receipt of a Fast Track designation from the U.S. Food and Drug Administration (FDA) for ACH-1625 for the treatmen...
|
|
Achillion Announces Preliminary Phase 1b Proof-of-Concept Data With ACH-2928 NS5A Inhibitor for the Treatment of Hepatitis C
Dec 5, 2011
|
13.8 KB |
|
| |
NEW HAVEN, Conn., Dec. 5, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported proof-of-concept data from its Phase 1b clinical trial of ACH-2928, a first-generation NS5A inhibitor, demonstrating th...
|
|
Achillion to Present at the 23rd Annual Piper Jaffray Health Care Conference
Nov 21, 2011
|
7.9 KB |
|
| |
NEW HAVEN, Conn., Nov. 21, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that members of the Company's executive team will present at the upcoming 23rd Annual Piper Jaffray Health Care Confe...
|
|
Achillion Reports Third Quarter and Nine Month 2011 Financial Results
Nov 8, 2011
|
17.7 KB |
|
| |
NEW HAVEN, Conn., Nov. 8, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today reported financial results for the three and nine months ended September 30, 2011. For the third quarter of 2011, Achillion repo...
|
|
Achillion to Present at the Credit Suisse 2011 Healthcare Conference
Nov 3, 2011
|
7.9 KB |
|
| |
NEW HAVEN, Conn., Nov. 3, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced that Dr. Milind Deshpande, President of Research and Development and Chief Scientific Officer, will provide a corporat...
|
|
Achillion Announces Nomination of Second Generation NS5A Inhibitor for the Treatment of Hepatitis C
Oct 13, 2011
|
11.2 KB |
|
| |
NEW HAVEN, Conn., Oct. 13, 2011 (GLOBE NEWSWIRE) -- Achillion Pharmaceuticals, Inc. (Nasdaq:ACHN), a leader in the discovery and development of small molecule drugs to combat the most challenging infectious diseases, today announced the nomination of an additional clinical candidate for the treatment of the hepatitis C virus (HCV) from its NS5A inh...
|
|
|
= add release to Briefcase
|
